- Home
- ZTO vs GMAB Comparison
ZTO vs GMAB Comparison
Compare ZTO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTO
- GMAB
- Stock Information
- Founded
- ZTO 2002
- GMAB 1999
- Country
- ZTO China
- GMAB Denmark
- Employees
- ZTO N/A
- GMAB N/A
- Industry
- ZTO Advertising
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ZTO Consumer Discretionary
- GMAB Health Care
- Exchange
- ZTO Nasdaq
- GMAB Nasdaq
- Market Cap
- ZTO 13.4B
- GMAB 13.7B
- IPO Year
- ZTO 2016
- GMAB N/A
- Fundamental
- Price
- ZTO $17.06
- GMAB $21.56
- Analyst Decision
- ZTO Buy
- GMAB Buy
- Analyst Count
- ZTO 5
- GMAB 9
- Target Price
- ZTO $22.64
- GMAB $39.17
- AVG Volume (30 Days)
- ZTO 2.8M
- GMAB 1.3M
- Earning Date
- ZTO 08-19-2025
- GMAB 08-07-2025
- Dividend Yield
- ZTO 4.10%
- GMAB N/A
- EPS Growth
- ZTO N/A
- GMAB 276.80
- EPS
- ZTO 1.22
- GMAB 18.36
- Revenue
- ZTO $6,230,576,589.00
- GMAB $3,230,902,140.00
- Revenue This Year
- ZTO $16.57
- GMAB $747.74
- Revenue Next Year
- ZTO $12.82
- GMAB $14.81
- P/E Ratio
- ZTO $13.97
- GMAB $11.65
- Revenue Growth
- ZTO 14.76
- GMAB 25.43
- 52 Week Low
- ZTO $16.34
- GMAB $17.24
- 52 Week High
- ZTO $27.50
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- ZTO 41.83
- GMAB 49.79
- Support Level
- ZTO $17.39
- GMAB $22.70
- Resistance Level
- ZTO $17.92
- GMAB $23.13
- Average True Range (ATR)
- ZTO 0.25
- GMAB 0.40
- MACD
- ZTO 0.04
- GMAB -0.04
- Stochastic Oscillator
- ZTO 11.17
- GMAB 38.67
About ZTO ZTO Express (Cayman) Inc. each representing one ordinary share.
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 22.1% in 2022. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 77% voting rights as of June 30, 2023. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 11.7% interest.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.